Urine metabolite profiles predictive of human kidney allograft status

Karsten Suhre, Joseph E. Schwartz, Vijay K. Sharma, Qiuying Chen, John R. Lee, Thangamani Muthukumar, Darshana M. Dadhania, Ruchuang DIng, David N. Ikle, Nancy D. Bridges, Nikki M. Williams, Gabi Kastenmüller, Edward D. Karoly, Robert P. Mohney, Michael Abecassis, John Friedewald, Stuart J. Knechtle, Yolanda T. Becker, Benjamin Samstein, Abraham Shaked & 2 others Steven S. Gross, Manikkam Suthanthiran

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Noninvasivediagnosis and prognosticationof acute cellular rejection in the kidney allograftmay help realize the full benefits of kidney transplantation. To investigate whether urinemetabolites predict kidney allograft status, we determined levels of 749metabolites in 1516 urine samples from 241 kidney graft recipients enrolled in the prospectivemulticenter Clinical Trials in Organ Transplantation-04 study. A metabolite signature of the ratio of 3-sialyllactose to xanthosine in biopsy specimen-matched urine supernatants best discriminated acute cellular rejection biopsy specimens from specimens without rejection. For clinical application, we developed a highthroughput mass spectrometry-based assay that enabled absolute and rapid quantification of the 3-sialyllactose-to-xanthosine ratio in urine samples. A composite signature of ratios of 3-sialyllactose to xanthosine and quinolinate to X-16397 and our previously reported urinary cellmRNAsignature of 18S ribosomal RNA, CD3 mRNA, and interferon-inducible protein-10 mRNA outperformed themetabolite signatures and the mRNA signature. The area under the receiver operating characteristics curve for the composite metabolite-mRNA signature was 0.93, and the signature was diagnostic of acute cellular rejection with a specificity of 84% and a sensitivity of 90%. The composite signature, developed using solely biopsy specimen-matched urine samples, predicted future acute cellular rejection when applied to pristine samples taken days to weeks before biopsy. We conclude that metabolite profiling of urine offers a noninvasive means of diagnosing and prognosticating acute cellular rejection in the human kidney allograft, and that the combined metabolite and mRNA signature is diagnostic and prognostic of acute cellular rejection with very high accuracy.

Original languageEnglish
Pages (from-to)626-636
Number of pages11
JournalJournal of the American Society of Nephrology
Volume27
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016
Externally publishedYes

Fingerprint

Allografts
Urine
Kidney
Messenger RNA
Biopsy
18S Ribosomal RNA
Chemokine CXCL10
Quinolinic Acid
Organ Transplantation
ROC Curve
Kidney Transplantation
Mass Spectrometry
Clinical Trials
Transplants
xanthosine
3'-sialyllactose

ASJC Scopus subject areas

  • Nephrology

Cite this

Urine metabolite profiles predictive of human kidney allograft status. / Suhre, Karsten; Schwartz, Joseph E.; Sharma, Vijay K.; Chen, Qiuying; Lee, John R.; Muthukumar, Thangamani; Dadhania, Darshana M.; DIng, Ruchuang; Ikle, David N.; Bridges, Nancy D.; Williams, Nikki M.; Kastenmüller, Gabi; Karoly, Edward D.; Mohney, Robert P.; Abecassis, Michael; Friedewald, John; Knechtle, Stuart J.; Becker, Yolanda T.; Samstein, Benjamin; Shaked, Abraham; Gross, Steven S.; Suthanthiran, Manikkam.

In: Journal of the American Society of Nephrology, Vol. 27, No. 2, 01.02.2016, p. 626-636.

Research output: Contribution to journalArticle

Suhre, K, Schwartz, JE, Sharma, VK, Chen, Q, Lee, JR, Muthukumar, T, Dadhania, DM, DIng, R, Ikle, DN, Bridges, ND, Williams, NM, Kastenmüller, G, Karoly, ED, Mohney, RP, Abecassis, M, Friedewald, J, Knechtle, SJ, Becker, YT, Samstein, B, Shaked, A, Gross, SS & Suthanthiran, M 2016, 'Urine metabolite profiles predictive of human kidney allograft status', Journal of the American Society of Nephrology, vol. 27, no. 2, pp. 626-636. https://doi.org/10.1681/ASN.2015010107
Suhre, Karsten ; Schwartz, Joseph E. ; Sharma, Vijay K. ; Chen, Qiuying ; Lee, John R. ; Muthukumar, Thangamani ; Dadhania, Darshana M. ; DIng, Ruchuang ; Ikle, David N. ; Bridges, Nancy D. ; Williams, Nikki M. ; Kastenmüller, Gabi ; Karoly, Edward D. ; Mohney, Robert P. ; Abecassis, Michael ; Friedewald, John ; Knechtle, Stuart J. ; Becker, Yolanda T. ; Samstein, Benjamin ; Shaked, Abraham ; Gross, Steven S. ; Suthanthiran, Manikkam. / Urine metabolite profiles predictive of human kidney allograft status. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 2. pp. 626-636.
@article{91a5999bd3e742f69436aa0a0c9f46c7,
title = "Urine metabolite profiles predictive of human kidney allograft status",
abstract = "Noninvasivediagnosis and prognosticationof acute cellular rejection in the kidney allograftmay help realize the full benefits of kidney transplantation. To investigate whether urinemetabolites predict kidney allograft status, we determined levels of 749metabolites in 1516 urine samples from 241 kidney graft recipients enrolled in the prospectivemulticenter Clinical Trials in Organ Transplantation-04 study. A metabolite signature of the ratio of 3-sialyllactose to xanthosine in biopsy specimen-matched urine supernatants best discriminated acute cellular rejection biopsy specimens from specimens without rejection. For clinical application, we developed a highthroughput mass spectrometry-based assay that enabled absolute and rapid quantification of the 3-sialyllactose-to-xanthosine ratio in urine samples. A composite signature of ratios of 3-sialyllactose to xanthosine and quinolinate to X-16397 and our previously reported urinary cellmRNAsignature of 18S ribosomal RNA, CD3 mRNA, and interferon-inducible protein-10 mRNA outperformed themetabolite signatures and the mRNA signature. The area under the receiver operating characteristics curve for the composite metabolite-mRNA signature was 0.93, and the signature was diagnostic of acute cellular rejection with a specificity of 84{\%} and a sensitivity of 90{\%}. The composite signature, developed using solely biopsy specimen-matched urine samples, predicted future acute cellular rejection when applied to pristine samples taken days to weeks before biopsy. We conclude that metabolite profiling of urine offers a noninvasive means of diagnosing and prognosticating acute cellular rejection in the human kidney allograft, and that the combined metabolite and mRNA signature is diagnostic and prognostic of acute cellular rejection with very high accuracy.",
author = "Karsten Suhre and Schwartz, {Joseph E.} and Sharma, {Vijay K.} and Qiuying Chen and Lee, {John R.} and Thangamani Muthukumar and Dadhania, {Darshana M.} and Ruchuang DIng and Ikle, {David N.} and Bridges, {Nancy D.} and Williams, {Nikki M.} and Gabi Kastenm{\"u}ller and Karoly, {Edward D.} and Mohney, {Robert P.} and Michael Abecassis and John Friedewald and Knechtle, {Stuart J.} and Becker, {Yolanda T.} and Benjamin Samstein and Abraham Shaked and Gross, {Steven S.} and Manikkam Suthanthiran",
year = "2016",
month = "2",
day = "1",
doi = "10.1681/ASN.2015010107",
language = "English",
volume = "27",
pages = "626--636",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Urine metabolite profiles predictive of human kidney allograft status

AU - Suhre, Karsten

AU - Schwartz, Joseph E.

AU - Sharma, Vijay K.

AU - Chen, Qiuying

AU - Lee, John R.

AU - Muthukumar, Thangamani

AU - Dadhania, Darshana M.

AU - DIng, Ruchuang

AU - Ikle, David N.

AU - Bridges, Nancy D.

AU - Williams, Nikki M.

AU - Kastenmüller, Gabi

AU - Karoly, Edward D.

AU - Mohney, Robert P.

AU - Abecassis, Michael

AU - Friedewald, John

AU - Knechtle, Stuart J.

AU - Becker, Yolanda T.

AU - Samstein, Benjamin

AU - Shaked, Abraham

AU - Gross, Steven S.

AU - Suthanthiran, Manikkam

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Noninvasivediagnosis and prognosticationof acute cellular rejection in the kidney allograftmay help realize the full benefits of kidney transplantation. To investigate whether urinemetabolites predict kidney allograft status, we determined levels of 749metabolites in 1516 urine samples from 241 kidney graft recipients enrolled in the prospectivemulticenter Clinical Trials in Organ Transplantation-04 study. A metabolite signature of the ratio of 3-sialyllactose to xanthosine in biopsy specimen-matched urine supernatants best discriminated acute cellular rejection biopsy specimens from specimens without rejection. For clinical application, we developed a highthroughput mass spectrometry-based assay that enabled absolute and rapid quantification of the 3-sialyllactose-to-xanthosine ratio in urine samples. A composite signature of ratios of 3-sialyllactose to xanthosine and quinolinate to X-16397 and our previously reported urinary cellmRNAsignature of 18S ribosomal RNA, CD3 mRNA, and interferon-inducible protein-10 mRNA outperformed themetabolite signatures and the mRNA signature. The area under the receiver operating characteristics curve for the composite metabolite-mRNA signature was 0.93, and the signature was diagnostic of acute cellular rejection with a specificity of 84% and a sensitivity of 90%. The composite signature, developed using solely biopsy specimen-matched urine samples, predicted future acute cellular rejection when applied to pristine samples taken days to weeks before biopsy. We conclude that metabolite profiling of urine offers a noninvasive means of diagnosing and prognosticating acute cellular rejection in the human kidney allograft, and that the combined metabolite and mRNA signature is diagnostic and prognostic of acute cellular rejection with very high accuracy.

AB - Noninvasivediagnosis and prognosticationof acute cellular rejection in the kidney allograftmay help realize the full benefits of kidney transplantation. To investigate whether urinemetabolites predict kidney allograft status, we determined levels of 749metabolites in 1516 urine samples from 241 kidney graft recipients enrolled in the prospectivemulticenter Clinical Trials in Organ Transplantation-04 study. A metabolite signature of the ratio of 3-sialyllactose to xanthosine in biopsy specimen-matched urine supernatants best discriminated acute cellular rejection biopsy specimens from specimens without rejection. For clinical application, we developed a highthroughput mass spectrometry-based assay that enabled absolute and rapid quantification of the 3-sialyllactose-to-xanthosine ratio in urine samples. A composite signature of ratios of 3-sialyllactose to xanthosine and quinolinate to X-16397 and our previously reported urinary cellmRNAsignature of 18S ribosomal RNA, CD3 mRNA, and interferon-inducible protein-10 mRNA outperformed themetabolite signatures and the mRNA signature. The area under the receiver operating characteristics curve for the composite metabolite-mRNA signature was 0.93, and the signature was diagnostic of acute cellular rejection with a specificity of 84% and a sensitivity of 90%. The composite signature, developed using solely biopsy specimen-matched urine samples, predicted future acute cellular rejection when applied to pristine samples taken days to weeks before biopsy. We conclude that metabolite profiling of urine offers a noninvasive means of diagnosing and prognosticating acute cellular rejection in the human kidney allograft, and that the combined metabolite and mRNA signature is diagnostic and prognostic of acute cellular rejection with very high accuracy.

UR - http://www.scopus.com/inward/record.url?scp=84970922503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970922503&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015010107

DO - 10.1681/ASN.2015010107

M3 - Article

VL - 27

SP - 626

EP - 636

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 2

ER -